Barclays analyst Manav Patnaik maintains Gartner (NYSE:IT) with a Equal-Weight and lowers the price target from $325 to $265.
What’s Going On With Altamira Therapeutics Stock?
Altamira Therapeutics shares are trading higher Thursday after the company announced highlights from its NASAR clinical trial with Bentrio nasal spray were published in video format on the social media channels of the allergology journal, "Allergy."
